Overview

Phase 2 Study Comparing the Safety and Efficacy of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Status:
Not yet recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with NSCLC or RCC

Phase:

Phase 2

Details

Lead Sponsor:

ImmuneSensor Therapeutics Inc.

Treatments:

Immune Checkpoint Inhibitors
Nivolumab
Pembrolizumab